Viral sensitizers potential infection of cancer cells via NF-kappaB

Background: Genetically engineered oncolytic viruses (OVs) can be effective anti-cancer agents. However, the heterogeneity of tumours and attenuation of OVs can limit their efficacy. Our group has previously shown that small molecules called Viral Sensitizers (VSes) used in combination with OVs can potentiate the infection of cancer cells up to over 1000-fold resulting in tumour specific killing both in vitro and in mouse tumour...